Pfizer has recently conducted their Phase III COVID-19 vaccine trial, resulting in 90% efficacy. This outcome, paired with continued progress on other COVID-19 vaccines, therapeutics, and treatments, generates hope for a faster return to normalcy. The second half of 2021 will be a ramp up period towards societal “normalcy”, with a return to normal life for most people occurring sometime in 2022.
Please click here to read a brief interview between healthcare analyst, Andrew Waight, and Altrinsic’s Head of Client Experience, Sara Sikes, regarding the vaccine development.